These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 21994366)

  • 1. The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity.
    Wang X; Sirianni A; Pei Z; Cormier K; Smith K; Jiang J; Zhou S; Wang H; Zhao R; Yano H; Kim JE; Li W; Kristal BS; Ferrante RJ; Friedlander RM
    J Neurosci; 2011 Oct; 31(41):14496-507. PubMed ID: 21994366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.
    Gafni J; Papanikolaou T; Degiacomo F; Holcomb J; Chen S; Menalled L; Kudwa A; Fitzpatrick J; Miller S; Ramboz S; Tuunanen PI; Lehtimäki KK; Yang XW; Park L; Kwak S; Howland D; Park H; Ellerby LM
    J Neurosci; 2012 May; 32(22):7454-65. PubMed ID: 22649225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
    Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
    J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.
    Doria JG; Silva FR; de Souza JM; Vieira LB; Carvalho TG; Reis HJ; Pereira GS; Dobransky T; Ribeiro FM
    Br J Pharmacol; 2013 Jun; 169(4):909-21. PubMed ID: 23489026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis.
    Zhang Y; Cook A; Kim J; Baranov SV; Jiang J; Smith K; Cormier K; Bennett E; Browser RP; Day AL; Carlisle DL; Ferrante RJ; Wang X; Friedlander RM
    Neurobiol Dis; 2013 Jul; 55():26-35. PubMed ID: 23537713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The melatonin receptor MT1 is required for the differential regulatory actions of melatonin on neuronal 'clock' gene expression in striatal neurons in vitro.
    Imbesi M; Arslan AD; Yildiz S; Sharma R; Gavin D; Tun N; Manev H; Uz T
    J Pineal Res; 2009 Jan; 46(1):87-94. PubMed ID: 18798788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene structures, biochemical characterization and distribution of rat melatonin receptors.
    Ishii H; Tanaka N; Kobayashi M; Kato M; Sakuma Y
    J Physiol Sci; 2009 Jan; 59(1):37-47. PubMed ID: 19340560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets.
    Jiang M; Wang J; Fu J; Du L; Jeong H; West T; Xiang L; Peng Q; Hou Z; Cai H; Seredenina T; Arbez N; Zhu S; Sommers K; Qian J; Zhang J; Mori S; Yang XW; Tamashiro KL; Aja S; Moran TH; Luthi-Carter R; Martin B; Maudsley S; Mattson MP; Cichewicz RH; Ross CA; Holtzman DM; Krainc D; Duan W
    Nat Med; 2011 Dec; 18(1):153-8. PubMed ID: 22179319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of melatonin membrane receptors increases calcium-binding proteins and protects VSC4.1 motoneurons from glutamate toxicity through multiple mechanisms.
    Das A; Wallace G; Reiter RJ; Varma AK; Ray SK; Banik NL
    J Pineal Res; 2013 Jan; 54(1):58-68. PubMed ID: 22823500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dithiol-based compounds maintain expression of antioxidant protein peroxiredoxin 1 that counteracts toxicity of mutant huntingtin.
    Pitts A; Dailey K; Newington JT; Chien A; Arseneault R; Cann T; Thompson LM; Cumming RC
    J Biol Chem; 2012 Jun; 287(27):22717-29. PubMed ID: 22577145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.
    Shirendeb U; Reddy AP; Manczak M; Calkins MJ; Mao P; Tagle DA; Reddy PH
    Hum Mol Genet; 2011 Apr; 20(7):1438-55. PubMed ID: 21257639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained effects of nonallele-specific Huntingtin silencing.
    Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
    Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
    Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
    J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatial and temporal requirements for huntingtin (Htt) in neuronal migration and survival during brain development.
    Tong Y; Ha TJ; Liu L; Nishimoto A; Reiner A; Goldowitz D
    J Neurosci; 2011 Oct; 31(41):14794-9. PubMed ID: 21994396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin partially protects 661W cells from H
    Sánchez-Bretaño A; Baba K; Janjua U; Piano I; Gargini C; Tosini G
    Mol Vis; 2017; 23():844-852. PubMed ID: 29259391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.
    Tang TS; Guo C; Wang H; Chen X; Bezprozvanny I
    J Neurosci; 2009 Feb; 29(5):1257-66. PubMed ID: 19193873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.